Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Novartis AG (NYSE: NVS) announced the voluntary withdrawal of its Type II variation application to...
Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology
Johnson & Johnson (J&J, NYSE: JNJ) announced on 24 April 2026 a definitive agreement to...
NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting
China’s National Medical Products Administration (NMPA) has issued a new regulatory framework clarifying post-approval obligations...
Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....
AstraZeneca Secures Dual NMPA Approvals for Imfinzi-Based Regimens in Advanced Hepatocellular Carcinoma and NSCLC
AstraZeneca plc (NYSE: AZN) announced that China’s National Medical Products Administration (NMPA) has granted approvals...
Insilico Medicine Advances AI-Designed PRMT5 Inhibitor ISM0387 for Glioblastoma with Sub-12-Month Discovery Timeline
Insilico Medicine (HKG: 3696), a China-based artificial intelligence (AI) drug discovery platform, announced the selection...
Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider
Star Sports Medicine Co., Ltd., a Chinese sports medical device manufacturer, successfully completed its initial...
Huadong Medicine Secures NMPA Approval for Ellansé M PCL Microsphere Filler for Temple Hollowing Correction
Huadong Medicine Co., Ltd. (SHE: 000963) announced it has received marketing approval from China’s National...
Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market
Sisram Medical Ltd (HKG: 1696), an Israel-based aesthetic medical technology company and subsidiary of Fosun...
China Medical System’s Comekibart Anti-IL-4Rα Antibody Enters NMPA Review for Seasonal Allergic Rhinitis
China Medical System Holdings Limited (CMS; HKG: 0867) announced that the National Medical Products Administration...
AbbVie Receives FDA Complete Response Letter for TrenibotE with Manufacturing Clarifications Requested
AbbVie Inc. (NYSE: ABBV) disclosed on April 23, 2026, that it has received a Complete...
Regeneron Secures FDA Approval for Otarmeni Gene Therapy and Announces Landmark U.S. Pricing Agreement
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has...
Thermo Fisher Scientific Reports 6% Revenue Growth in Q1 2026 Driven by Innovative Product Launches and Strategic AI Collaboration
Thermo Fisher Scientific Inc. (NYSE: TMO) announced first-quarter 2026 financial results with revenue growing 6%...
China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework
China’s National Health Commission (NHC) released a draft notification for public consultation on comprehensive revisions...
SciClone Pharmaceuticals Partners with JD Healthcare to Pioneer Integrated Immune Health Management Model
SciClone Pharmaceuticals Inc (HKG: 6600) announced a strategic partnership agreement with JD Healthcare (HKG: 6618),...
Roche Q1 Sales Rise 6% Driven by Innovative Medicines as China Expansion and Diagnostics Recovery Offset Currency Headwinds
Roche AG (SWX: ROP, OTCMKTS: RHHBY) reported first-quarter 2026 group sales of CHF 14.7 billion...
Transcenta Presents Promising Pre-clinical Data for Proprietary LIV1 Antibody-Drug Conjugate at AACR 2026
Transcenta Holdings Ltd (HKG: 6628) has presented pre-clinical data for its proprietary LIV1 antibody-drug conjugate...
Simcere Pharmaceutical Withdraws NDA for Rademikibart in Atopic Dermatitis, Plans Resubmission Later This Month
Simcere Pharmaceutical Group Limited (HKG: 2096) has withdrawn its New Drug Application (NDA) for rademikibart...
Hengrui Pharmaceuticals Reports Strong Q1 2026 Results with 12.98% Revenue Growth and Multiple New Drug Approvals
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) has released its first quarter 2026...
Mebanks Divests Guangzhou Specialty Pharmacy Subsidiary to DaShenLin for $7.75 Million to Focus on Higher-Margin Health Insurance and Management Businesses
Sipai Health Technology Co., Ltd. (HKG: 0314), also known as Mebanks, has announced the sale...